PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study

Inclusion Criteria: All subjects

• Affiliation to a social security scheme, universal medical coverage (CMU) or anyequivalent scheme
• Physical state compatible with the carrying out of the investigations according to thejudgment of the investigator
• Procedure for obtaining consent For HFpEF patients:
• Hospitalization in one of the partner hospitals in the last 30 months
• With a diagnosis of symptomatic congestive heart failure (NYHA II to IV)
• With a plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or havinghad an administration of a dose of intravenous diuretics during hospitalization forcongestive heart failure
• Left ventricular ejection fraction ≥ 50%
• Hospital discharge for at least 2 months For HFrEF patients:
• Hospitalization in one of the partner hospitals in the last 30 months
• With a diagnosis of symptomatic congestive heart failure (NYHA II to IV)
• Plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or administered adose of intravenous diuretics during hospitalization for congestive heart failure
• Hospital discharge for at least 2 months
• Left ventricular ejection fraction ≤ 40%
• Matched age and sex to HFpEF patients (for participants to extensive phenotyping) For subjects apparently without heart failure :
• Subject without a notable medical history or medical history within the last 5 years
• Normotensive or who may have an essential hypertension of grade 1 (≤159 / 99 mmHg),treated or not
• Can present a dyslipidemia, treated by hygieno-dietetic measures alone
• Sinus heart rate
• Estimated glomerular filtration rate ≥ 60 ml / min (CKD epi)
• Matched age and sex to HFpEF patients (for participants to extensive phenotyping)

Exclusion Criteria: All subjects

• Pregnancy or breastfeeding

• Participation in another interventional study

• Person placed under the safeguard of justice

• Subject that can not understand the procedures related to the protocol

• Severe obesity (BMI > 40 Kg / m2)

• For those performing the injected MRI: Patient who has already had a severe allergy togadolinium MRI contrast agents

• For those performing the injected MRI: MRI usual contraindications: Pace-maker,defibrillator, metallic objects

• Administration of a vaccine dose (including anti-Sars-Cov-2) less than 3 weeks old For both HFpEF and HFrEF patients:

• History of right ventricular infarction

• History of cardiac transplantation or circulatory assistance

• Major surgery scheduled for less than 6 months, coronary revascularization of lessthan 3 months

• Pacemaker or any implanted device (or foreign body) not compatible with MRI

• Presence of very severe co-morbidity: end-stage renal failure (GFR <15ml / min),severe chronic obstructive pulmonary disease (COPD), severe valve disease (includingsevere aortic stenosis), organ transplantation

• Hypertrophic cardiomyopathy of known genetic cause

• Hereditary amyloidosis with disabling neuropathy

• Amyloidosis under specific treatment

• Other antecedent of known congenital heart disease type, Post-embolic chronicpulmonary heart, Restrictive Cardiopathy, Diagnosed Fabry Disease For HFpEF patients:

• History of systolic dysfunction with proven LVEF reduction (≤ 40%) For subjects apparently without heart failure :

• Medication use other than pure systemic or local estrogen / progestin and progestincontraceptives and paracetamol, at the discretion of the investigator

• Acute pathology within 8 days prior to inclusion

• Cardiac or vascular organic impairment or apparent chronic diseases

• Chronic treatment outside a treatment for high blood pressure

• Having already had ≥3 MRI with injection of gadolinium contrast agents